Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

NCT04553939 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER_GOV

Sponsor class

Conditions

Urothelial Carcinoma
Bladder Cancer

Interventions

DRUG: Toripalimab
DRUG: Gemcitabine

Sponsor

Henan Cancer Hospital